Clinical Trials


Safety and Pharmacokinetic Trial in Healthy HIV-Negative Women to Assess the Delivery of Dapivirine From a Vaginal Ring

This study has been completed
International Partnership for Microbicides, Inc.

Information provided by (Responsible Party)
International Partnership for Microbicides, Inc. Identifier

First received: September 29, 2016
Last updated: September 5, 2017
Last Verified: September 2017
History of Changes


The proposed study is a single center, double-blind placebo-controlled trial to assess the safety and tolerability of the dapivirine ring as compared to a placebo ring when inserted for 28 days in 16 healthy, HIV-negative women.

Condition Intervention Phase
HIV Infections

Combination Product : Dapivirine Vaginal Ring
Combination Product : Placebo vaginal ring
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Double-Blind, Randomised, Placebo-Controlled Safety and Pharmacokinetic Trial in Healthy HIV-Negative Women to Assess Delivery of Dapivirine From the Matrix Vaginal Ring Containing 25 MG of Dapivirine

Further study details as provided by International Partnership for Microbicides, Inc.:

Primary Outcome Measures

  • Safety: To assess the safety and tolerability of the dapivirine vaginal ring, the endpoint was the proportion of women on the dapivirine or placebo ring experiencing specific, protocol-defined safety events during the study (see description). [ Time Frame: 28 days ]
    mucosal abnormalities (as defined in the CONRAD/WHO manual) visible during naked eye examination and/or colposcopy positive diagnostic tests for trichomonas, gonorrhea, and/or chlamydia at least one AE during the trial period any laboratory abnormalities on hematology and biochemistry abnormal vaginal pH and/or abnormal vaginal flora during the course of the trial.
  • Pharmacokinetics: assessed by measurement of the concentrations of dapivirine in plasma and in vaginal fluids (collected by Tear Test Strips) before, during and after the trial period. [ Time Frame: 28 days ]

Enrollment: 16
Study Start Date: August 2009
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: Dapivirine Vaginal Ring
Vaginal ring containing 25 mg dapivirine
Combination Product: Dapivirine Vaginal Ring

A platinum-catalysed silicone elastomer matrix vaginal ring containing 25mg of dapivirine used over 28 days

Placebo Comparator: Placebo Vaginal Ring
Placebo vaginal ring
Combination Product: Placebo vaginal ring

Placebo vaginal ring containing no dapivirine

Detailed Description:

The objective of this trial was to evaluate the feasibility of using a platinum-catalyzed matrix vaginal ring, containing 25 mg of dapivirine, to deliver investigational product for 28 continuous days. The specific objectives were to:

  1. Assess the safety and tolerability of the vaginal ring containing dapivirine, when used continuously for 28 days, compared to a placebo ring
  2. Assess dapivirine concentrations in plasma before, during and after 28 days' use of a silicone elastomer matrix vaginal ring containing dapivirine
  3. Assess dapivirine concentrations in vaginal fluids before, during and after 28 days' use
of a silicone elastomer matrix vaginal ring containing dapivirine. Safety was evaluated from clinical evaluations, clinical laboratory test results and adverse events (AEs). The pharmacokinetic (PK) evaluation was made based on systemic absorption from plasma concentrations and local disposition from vaginal fluid concentrations.



Ages Eligible for Study: 18 Years to 40 Years  
Sexes Eligible for Study: Female  
Accepts Healthy Volunteers: Yes  


Inclusion Criteria:

  • were females between 18 and 40 years of age, inclusive
  • were willing and able to give written, informed consent
  • were available for all visits and consented to follow all procedures scheduled for the trial
  • were healthy, based on medical history, vital signs, physical examination, urinalysis (dipstick and microscopy), laboratory evaluations for genital infections (gonorrhea, chlamydia and trichomonas), and laboratory evaluations for hematology and biochemistry
  • were HIV-negative, as determined by an HIV test at screening
  • were willing to abstain from sexual activity for the duration of the period of ring use
  • were on a stable form of contraception, defined as a stable oral contraceptive regimen for at least two months prior to enrollment; OR a transdermal contraceptive patch for at least three months prior to enrollment; OR long-acting progestins for at least six months prior to enrollment; OR had an intra-uterine device (IUD) inserted (with no vaginal or gynecological complaints associated with its use) at least three months prior to enrollment; OR had undergone surgical sterilization at least three months prior to enrollment; AND were willing to use oral contraceptives, if necessary, to avoid menstruation while taking part in this trial
  • were asymptomatic for genital infections at the time of enrollment, and the cervix and vagina appeared normal upon pelvic examination and colposcopy, as determined by the investigator
  • were willing to refrain from the use of vaginal products or objects including, but not limited to, tampons, cotton wool, rags, diaphragms, cervical caps (or any other vaginal barrier method), douches, lubricants, vibrators/dildos, non-trial vaginal rings and drying agents for 14 days prior to enrollment and for the duration of the trial
  • were willing to refrain from participation in any other research trial for the duration of this trial
  • were willing to provide adequate locator information for trial retention purposes and were reachable per local standard procedures (e.g. by home visit or telephone, or via family or close neighbor contacts (confidentiality was to be maintained))
  • were hepatitis B and C negative at the time of screening.

Exclusion Criteria:
  • had a history of anaphylaxis or severe allergy resulting in angioedema, or a history of sensitivity/allergy to latex or silicone
  • were pregnant or breast-feeding, or had their last pregnancy outcome within three months prior to screening
  • were participating in any other clinical research trial involving investigational or marketed products at the time of this trial or within two months prior to screening
  • had a history or diagnosis of and/or treatment for a sexually transmitted disease within the previous three months
  • had a history of genital tract surgery within the previous two months
  • had a current diagnosis of sexually transmitted infections (STIs) (gonorrhea, chlamydia and/or trichomonas)
  • had current vulvar or vaginal symptoms/abnormalities that could influence the trial results
  • had a history of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding or urethral obstruction, incontinence or urge incontinence
  • had symptomatic genital herpes simplex virus (HSV) infection or a history of genital herpetic infection
  • had current non-iatrogenic pelvic/colposcopic examination findings involving deep epithelial disruption
  • had any Grade 2, 3 or 4 hematology, biochemistry or urinalysis laboratory abnormality at baseline (screening), according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading Adverse Events
  • had a Pap test result at screening that required cryotherapy, biopsy, treatment (other than for infection) or further evaluation; this included any findings of atypical squamous cells of undetermined significance (ASCUS)
  • had any condition(s) that, in the opinion of the investigator, could interfere with
adherence to trial requirements or evaluation of the trial objectives.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02920827


SGS Life Sciences Center
Antwerp, Flanders, Belgium

Sponsors and Collaborators

International Partnership for Microbicides, Inc.


Study Director: Annalene Nel, PhD IPM
More Information

More Information

Responsible Party: International Partnership for Microbicides, Inc. Identifier: NCT02920827   History of Changes  
Other Study ID Numbers: IPM024  
Study First Received: September 29, 2016  
Last Updated: September 5, 2017  
Individual Participant Data    
Plan to Share IPD: Undecided  

Keywords provided by International Partnership for Microbicides, Inc.:

HIV Infections
HIV seronegativity

Additional relevant MeSH terms:
HIV Infections
Dapivirine processed this data on May 24, 2020
This information is provided by